Stockreport

Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update [Yahoo! Finance]

Tharimmune, Inc.  (THAR) 
PDF initiate a Phase 2 study of its lead asset, TH104, in patients with moderate-to-severe pruritus associated with primary biliary cholangitis (PBC), a rare and chronic liv [Read more]